Retrospective 10,429 outpatients in France, 8,315 treated with HCQ+AZ a median of 4 days from symptom onset, showing significantly lower mortality with treatment.
Million et al., 5/27/2021, retrospective, France, Europe, preprint, 28 authors, dosage 200mg tid days 1-10.
risk of death, 83.0% lower, RR 0.17, p < 0.001, treatment 5 of 8315 (0.1%), control 11 of 2114 (0.5%), adjusted per study.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.